Evidence map›Paper›PMID 40113717›Full record

ArticleBreast cancer (Tokyo, Japan)2025

Effects of breast size on breast reconstruction in BRCA mutation carriers and genetic high-risk patients after bilateral mastectomy.

Martin C Lam, Vendela Grufman, Sonia Fertsch, Florian Recker, Nicole E Speck, Jian Farhadi

Abstract read
In one paragraph

Article in Breast cancer (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Martin C LamPlastic Surgery Group, Zurich, Switzerland. martin.lam.research@gmail.com.ORCID http://orcid.org/0000-0002-4073-7379
Vendela GrufmanPlastic Surgery Group, Zurich, Switzerland.
Sonia FertschPlastic Surgery Group, Zurich, Switzerland.
Florian ReckerDepartment of Gynecology and Obstetrics, University Hospital Bonn, University of Bonn, Bonn, Germany.
Nicole E SpeckPlastic Surgery Group, Zurich, Switzerland.
Jian FarhadiPlastic Surgery Group, Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWomen with genetic susceptibility to breast cancer and indication for bilateral mastectomy are more likely to undergo implant-based breast reconstruction (IBR) than autologous breast reconstruction (ABR), while the impact of breast size in this context is insufficiently studied. Ultimately, comparative data on IBR and different types of ABR beyond abdominal-based flaps in genetic susceptible women remain scarce. This study aimed to evaluate factors associated with ABR and the effects of breast size for bilateral reconstruction in high-risk patients.

methodsA 2.5-year retrospective study was conducted at a single institution including all genetic high-risk patients who underwent bilateral mastectomy and breast reconstruction. Patients were stratified into two groups based on the weight of the mastectomy specimen. Small breast sizes were defined by mastectomy weights below 400 g, and medium-to-large breasts by specimen weights above 400 g. Binary logistic regression was performed to assess variables predictive of ABR, followed by an analysis of the breast size-dependent reconstructive algorithm and its complication rates.

resultsWe included 71 patients with BRCA1/2 (97.2%), CHEK2 (1.4%), and PALB2 (1.4%) mutations in the study. Among those, 68 IBRs and 74 ABRs were performed. Increasing age, immediate reconstruction, and medium-to-large breast size were predictive of ABR compared to IBR (p < 0.05). In the IBR-group, the majority of preoperative small breasts received subpectoral implant placements (81.0%, p = 0.003), while prepectoral implants (53.9%, p = 0.003) were preferred in medium-to-large breasts. In the ABR-group, the deep inferior epigastric artery (DIEP) flap was the choice in the vast majority of cases with larger breasts (86.4%, p < 0.001), whereas the transverse myocutaneous gracilis (TMG) flap (46.7%, p < 0.001) and superior gluteal artery perforator (SGAP) flap (20.0%, p = 0.002) were only considered in small-breasted patients. No elevated incidence of overall complications with increasing breast size was found. However, patients with larger breasts were more likely to undergo elective revisions after IBR (p < 0.001) as well as ABR (p = 0.013). With regard to two-stage tissue expander reconstructions, high-risk patients with larger breast size revealed increased explantations (p = 0.043) and expander-related revisions requiring additional surgery (p = 0.003). The latter was significantly reduced by reduction mammoplasty prior to expander placement (p = 0.036).

conclusionsThe preoperative breast size of gene mutation carriers influences the postmastectomy reconstructive choice. TMG and SGAP flaps are suitable options for bilateral reconstruction of genetic susceptible patients with small breasts, while DIEP flaps are preferred in larger breast sizes. With increasing breast size an elevated risk for elective revisions after either IBR or ABR need to be considered. Women with medium-to-large breasts exhibit increased morbidity related to expansion and genetic high-risk patients may benefit from prior reduction mammoplasty.

Indexed as

BreastBreast NeoplasmsMammaplastyMastectomyAdultBRCA1 ProteinBRCA2 ProteinBreast ImplantsFemaleGenetic Predisposition to DiseaseHumansMiddle AgedMutationOrgan SizeRetrospective StudiesBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanAutologous breast reconstructionBilateral breast reconstructionBRCA mutation carriersEffects of breast sizeHereditary breast cancerImplant-based breast reconstructionPatients with high-risk breast cancerRisk-reducing mastectomy

Identifiers

PMID40113717
PMCPMC11993471

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.